Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial-Reference-Cited by-同舟云学术

Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial

Published:2018-08 Issue: Volume:99 Page:66-77
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Tejpar Sabine,Yan Pu,Piessevaux Hubert,Dietrich Daniel,Brauchli Peter,Klingbiel Dirk^ORCID,Fiocca Roberto^ORCID,Delorenzi Mauro^ORCID,Bosman Fred,Roth Arnaud D.

Funder

Pfizer

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference37 articles.

1. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports;Wasserman;Ann Oncol,1997

2. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer;Marcuello;Br J Cancer,2004

3. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review;Palomaki;Genet Med,2009

4. The role of pharmacogenetics in cancer therapeutics;Yong;Br J Clin Pharmacol,2006

5. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review;Glenn;Genet Med,2009

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms and emerging strategies for irinotecan-induced diarrhea;European Journal of Pharmacology;2024-07

2. Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer;World Journal of Gastrointestinal Oncology;2024-06-15

3. [Artículo traducido] Exploración del impacto de la farmacogenética en la medicina personalizada: una revisión sistemática;Farmacia Hospitalaria;2024-06

4. Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110);ESMO Open;2024-05

5. Exploring the impact of pharmacogenetics on personalized medicine: A systematic review;Farmacia Hospitalaria;2024-02